Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × olverembatinib × Sarcoma × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Sarcoma 1 Myeloid 1 Lymphoid 1

Conditions

Interventions

Doxorubicin 38 Radiotherapy 27 Ifosfamide 26 Vincristine 25 Cyclophosphamide 21 Etoposide 19 Imatinib Mesylate 18 Radiation 12 Dactinomycin 12 Filgrastim 11 Temozolomide 9 Trabectedin 8 Sunitinib 8 Methotrexate 8 Specimen Handling 6 Granulocyte Colony-Stimulating Factor 6 pazopanib 5 nilotinib 5 Zoledronic Acid 5 Magnetic Resonance Spectroscopy 5 Irinotecan 5 Cisplatin 5 Topotecan 4 Surgical Procedures, Operative 4 Procarbazine 4 Paclitaxel 4 Liposomes 4 Ibandronic Acid 4 Dexrazoxane 4 Dacarbazine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡